COMP <GO>
CRSP vs IMVT // ALTMAN Z-SCORE & DEBT/EQUITY
CRISPR Therapeutics AG (NASDAQ) VS. Immunovant Inc. (NASDAQ) • 15-METRIC TALLY: CRSP 5
— IMVT 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: IMVT
LAST: $49.99 (0.00%) • MKT CAP: $4.83B
balance-sheet
7.97
LAST: $29.04 (+2.22%) • MKT CAP: $5.87B
balance-sheet
26.00
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. IMVT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | IMVT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | -35.00% | +4.40 | CRSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | -6.65% | +0.06 | CRSP | /fcf-yield <GO> |
| Operating Margin | -60.00% | -36.00% | -24.00 | IMVT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -29.50% | -30.50 | IMVT | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 9.90% | -74.90 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 7.97 | 26.00 | -18.03 | IMVT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | IMVT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 36.4 | +7.60 | CRSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.98 | +0.14 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 36.0x | -8.00 | CRSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.83B | $5.87B | -$1.03B | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | IMVT REV | CRSP GROSS % | IMVT GROSS % | CRSP FCF | IMVT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $1.67B | — | — | -$345.9M | -$407.3M |
| FY 2024 | $37.3M | $1.37B | — | — | -$144.7M | -$376.6M |
| FY 2023 | $371.2M | $856.8M | — | — | -$277.1M | -$214.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
IMVT // BETA 0.98